Skip to content

Earnings call

Lupin Q3 FY25 earnings call: Lupin expects margins in the range of 22%-23% in the current fiscal year

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

The company expects margins in the range of 22%-23% in the current fiscal year. The company has more than 20 respiratory products and 40 injectable products in development and plans to file more than 30 ANDAs in the next 2 years, of which more than 50% will be complex products. The company improved profitability in its US business through better product mix and higher efficiencies in the base business in Q3 Financial year ’2025. Spiriva TRx share reached 38% in January and NRx was 40% plus; the company hopes to sustain this level through the rest of the quarter and into the next fiscal year to reach overall market share of 40% plus. Operating working capital was INR 7,071 crores as on 31st December, compared with INR 5,691 crores as of 31st March 2024, translating to 113 days of net working capital versus 105 days as of 31st March 2024.

The numbers management gave

Results

  • The company improved profitability in its US business through better product mix and higher efficiencies in the base business in Q3 Financial year ’2025.
    Show source
    We continue to improv e our profitability in the US, led by better product mix and higher efficiencies in the base business.
  • India business grew 11.9% YoY, led by its India Formulations business and additional tenders in its Global Institutional business, in Q3 Financial year ’2025.
    Show source
    Coming to India, we reported growth of 11.9% YoY led by growth in India Formulations business and additional tenders in our Global Institutional business.
  • India Formulation business grew 9.1% for the 9M this fiscal year, against IPM growth of 8.2%.
    Show source
    Our India Formulation business recorded growth of 9.1% for the 9M this fiscal year against an IPM growth of 8.2%.
  • Diabetes, Cardiac and GI therapies grew ahead of the market and its chronic share increased, while muted growth in the respiratory category affected overall performance in Q3 Financial year ’2025.
    Show source
    While key therapies like Diabetes, Cardiac, GI grew ahead of the market and we also increased our chronic share, muted growth in the respiratory category affected our overall performance during the quarter.
  • R&D as a percentage of sales was 7.7% during the quarter and 7.4% for the 9M.
    Show source
    Switching to R&D, our R&D as % to sales was at 7.7% during the quarter and 7.4% for the 9M.
  • India business grew 11.9% YoY, North America grew 12.3% YoY, EMEA grew 20.9% YoY and API grew 4% YoY in Q3 Financial year ’2025.
    Show source
    India business has grown by 11.9% YoY, North America has grown 12.3% YoY, EMEA grew 20.9% YoY whil st API grew 4% YoY.
Show 24 more statements

Results

  • US business recorded sales of USD 235 million, growth of 10.5% YoY and 6.8% QoQ on constant currency basis during the quarter.
    Show source
    US Business During the quarter, the US business recorded sales of USD 235 million, a growth of 10.5% YoY and 6.8% QoQ on constant currency basis.
  • US sales were USD 682 million on a 9M basis, growth of 12.5% compared with 9M of FY24.
    Show source
    On a 9M basis, US sales were USD 682 million, a growth of 12.5% as compared to 9M of FY24.
  • India business grew 11.9% YoY during the quarter and 16% YoY during the 9MFY25 period.
    Show source
    India The India business has grown by 11.9% YoY during the quarter and 16% YoY during the 9MFY25 period.
  • Prescription business grew 5.8% YoY during Q3FY25.
    Show source
    Within this, the prescription business has grown 5.8% YoY during Q3FY25.
  • Chronic share was 65% during the quarter, with Diabetes and Cardiology growing ahead of IPM growth.
    Show source
    Chronic share during the quarter was higher at 65% with key segments like Diabetes and Cardiology growing ahead of the IPM growth.
  • In-licensed products had a share of around 12%, similar to 12% last year, and positively impact profitability going ahead.
    Show source
    The share of in-licensed products is around 12% similar to the 12% last year, which also positively impacts our profitability, going ahead.
  • Ex-India, ex-North America Formulation businesses, including EMEA, ROW and Emerging Markets, increased revenues 7.5% YoY to INR 1,277 crores and constituted 23% of sales.
    Show source
    Other Businesses Revenues in our ex -India, ex North America Formulation businesses which include EMEA, ROW and Emerging Markets have increased 7.5% YoY to INR 1,277 crores and now constitute 23% of our sales.
  • Gross margins were 69.4% in Q3FY25, up from 66.0% in Q3 last year, and 69% on a 9M basis versus 65.7% in the similar period last year, an improvement of 334 bps points; the improvement was driven by better product mix, tail winds on input costs, lower share of in-licensed products, increased volumes, and cost improvement and efficiencies undertaken over the last several quarters.
    Show source
    Gross Margins Coming to the profitability, Q3FY25 gross margins were 69.4% up from 66.0% in Q3 last year.
  • Employee benefit expense was INR 984 crores in Q3FY25, up 10.7% YoY from INR 889 crores in Q3FY24 and translating into 17.5% of sales; on a 9M basis, it was INR 2,963 crores, up 14.2% YoY and translating into 17.8% of sales versus 17.6% in the corresponding period last year, largely due to regular annual increments and business growth.
    Show source
    Employee Benefit expense Employee Benefit expense at INR 984 crores increased 10.7% YoY from INR 889 crores in Q3FY24 translating into 17.5% of sales.
  • Manufacturing and other expenses were INR 1,696 crores in Q3FY25, increasing 8.7% YoY from INR 1,560 crores in Q3FY24, and were 30.2% of sales versus 30.7% last year; on a 9M basis, manufacturing expenses were INR 4,936 crores, up 7.7% YoY and 29.7% of sales versus 31.0% in the corresponding period last year, mainly due to higher R&D costs and higher volumes in the normal course of business.
    Show source
    Manufacturing & Other Expenses Q3FY25 came in at INR 1,696 crores, increasing 8.7% YoY from INR 1,667 crores in Q2 FY25 and INR 1,560 crores in Q3FY24 translating to 30.2% of sales versus 30.7% last year.
  • R&D was INR 434 crores, 7.7% of sales, in Q3FY25, compared with INR 448 crores, 8.2% of sales, in Q2 FY25, with almost two thirds of R&D directed towards complex portfolio; on a 9M basis, R&D was INR 1,232 crores or 7.4% of sales.
    Show source
    R&D R&D is at INR 434 crores, 7.7% of sales as compared to INR 448 crores, 8.2 % of sales in Q2 FY25, with almost two thirds of our R&D directed towards complex portfolio.
  • EBITDA excluding Forex and other income was INR 1,366 crores versus INR 1,022 crores last year, an increase of 33.7% YoY, with margins of 24.3% versus 20.1% last year in the same period.
    Show source
    Page 5 of 18 February 12, 2025 EBITDA Excluding Forex and other income, EBITDA was INR 1,366 crores versus INR 1,022 crores last year, an increase of 33.7% YoY, with margins of 24.3% versus 20.1% last year in the same period.
  • EBITDA margins expanded 51bps QoQ against a backdrop of higher gross margins and lower fixed costs during the period.
    Show source
    On a QoQ basis, margins have expanded 51bps.
  • EBITDA on a 9M basis was INR 3,985 crores, up 42.1% YoY, with margins of 24% compared with 19% in the corresponding period last year.
    Show source
    On a 9M basis, EBITDA was at INR 3,985 crores, up 42.1% YoY with margins of 24% as compared to 19% in the corresponding period last year.
  • ETR was 19.1% during 9MFY25.
    Show source
    Tax As far as the ETR is concerned it was 19.1% during 9MFY25.
  • Respiratory business grew 3% for nine months, while the market grew 4% for nine months, and the respiratory business’s quarter was disappointing.
    Show source
    We were at 3% for nine months and I mean the quarter again has been disappointing.
  • Respiratory business has lagged the rest of the market for a while, after periods of high double-digit growth, and has been slow for the last 12-16 months.
    Show source
    I mean we've had periods of high double-digit growth on respiratory but for the last 12-16 months, it's just been slow.
  • US business had revenues at a five year high this quarter, led by volume growth in inline products and contributions from new products like Mirabegron, which helped offset anticipated competition in Albuterol and Suprep®.
    Show source
    Our US business delivered strong QoQ and YoY growth this quarter with revenues at a five year high.
  • US business benefited from volume growth in inline products and new product introductions, offset by low single digit price declines in base products and anticipated new generic competition in Albuterol and Suprep®.
    Show source
    As Vinita mentions, while we have benefited from volume growth in inline products and new product introductions, this has been offset by low single digit price declines in base products and anticipated new generic competition in products like Albuterol and Suprep®.
  • Higher other operating income was mainly due to higher PLI and export benefits during the quarter.
    Show source
    This increase is mainly due to higher PLI and export benefits during the quarter.
  • Conservative provision is coming from litigations, which it does not identify.
    Show source
    It's a conservative provision and that's what it is.
  • The company has seen some good results from its continuing focus on cost. Replaced by a later filing.
    Show source
    But the focus on cost is eternal insofar as we are concerned and we have seen some good results coming in.

Money and capital

  • The company is debt-free and has the ability to invest in the right programs and opportunities.
    Show source
    And you know that we are a debt-free company at this point, so have the ability to invest for the right programs and opportunities.
  • Operating working capital was INR 7,071 crores as on 31st December, compared with INR 5,691 crores as of 31st March 2024, translating to 113 days of net working capital versus 105 days as of 31st March 2024. Replaced by a later filing.

What it expects ahead

What management expects

  • The company expects margins in the range of 22%-23% in the current fiscal year.
    Show source
    We feel confident of maintaining our growth momentum going ahead with margins in the range of 22%-23% in the current fiscal year.
  • The company believes its pipeline will enable complex products to exceed 50% of its portfolio over the next couple of years.
    Show source
    We believe that our pipeline will enable us to continue to drive the shift to complex products to over 50% of our portfolio over the next couple of years.
  • The company expects R&D to be around INR 1,800 crores for fiscal year 25, with a significant increase in R&D spends in Q4; Lupin expects R&D to be around INR 1,750-1,800 crores for the full year, with a significant increase in R&D in Q4.
    Show source
    For the full year, we expect R&D to be around INR 1,750-1,800 crores with a significant increase in R&D in Q4.
  • The company expects its ETR to be around 20-21% for the full year.
    Show source
    For the full year, we expect the ETR to be around 20-21%.
  • The company expects overall margins of 22.5% to 23.5% to be a good range to aim for the next fiscal.
    Show source
    But I think if you talk about overall margins, I did indicate the fact that between 22.5% to 23.5% would be a good range to aim for the next fiscal as well.
  • The company anticipates bringing Glucagon, Risperdal Consta and Liraglutide to market next fiscal year, alongside Tolvaptan, to help deliver strong growth.
    Show source
    Apart from key products like Tolvaptan, we have an exciting portfolio of injectable products like Glucagon, Risperdal Consta, Liraglutide which we anticipate bringing to market next fiscal year that should help us deliver strong growth in the year .
Show 11 more statements

What management expects

  • The company anticipates its US business will deliver double digit growth on a full year FY25 basis, ahead of its earlier guidance of high single digit growth in the segment.
    Show source
    On a full year FY25 basis, we anticipate our US business to deliver double digit growth, ahead of our earlier guidance of high single digit growth in the segment.
  • Major products for next year are Tolvaptan and Glucagon, Risperdal Consta and potentially Liraglutide.
    Show source
    Vinita Gupta: The major products are Tolvaptan and Glucagon, Risperdal Consta and potentially Liraglutide.
  • The company is making progress on its Glucagon and Risperdal Consta applications with the agency and would expect approval sooner rather than later.
    Show source
    Vinita Gupta: So we are making progress on both applications with the agency and would expect that hopefully, approval sooner rather than later.
  • The company expects Tolvaptan to be the major contributor in the first half of the fiscal year and injectables to ramp up in the second half.
    Show source
    But I think it'll be safe to assume that Tolvaptan would be the major contributor in the first half of the fiscal year and the injectables should ramp up in the second half very nicely.
  • The company believes its respiratory business will bounce back, hopefully in the next couple of quarters.
    Show source
    But we believe that it'll bounce back, hopefully in the next couple of quarters.
  • The benefit from inhalers is there for the next three years.
    Show source
    Ramesh Swaminathan: The benefit is there for next three years.
  • The company assumes additional competition will come in the second half of the year.
    Show source
    Vinita Gupta: We assume that additional competition comes in, in the second half of the year.
  • The company has assumed that Albuterol has already started to face competition or its impact.
    Show source
    On Mirabegron, we've assumed that Albuterol faces competition or impact of competition that has already started.
  • The company has assumed Tolvaptan will help tremendously in the first half, and injectables plus Tolvaptan will help in the second half.
    Show source
    And we've assumed that Tolvaptan helps tremendously in the first half and injectables plus Tolvaptan in the second half.
  • R&D spend will increase in absolute terms in FY26, while remaining around the same levels as a percentage of sales.
    Show source
    Ramesh Swaminathan: I would say, as an absolute there would be an increase but as a percentage of sales, it will perhaps be around the same levels.
  • The company expects R&D to be around INR 1,750-1,800 crores for the full year, with a significant increase in R&D in Q4. Replaced by a later filing.

What it is building and selling

Projects and capacity

  • The company has more than 20 respiratory products and 40 injectable products in development and plans to file more than 30 ANDAs in the next 2 years, of which more than 50% will be complex products.
    Show source
    We have an exciting pipeline, with more than 20 respiratory products and 40 injectable products in development and plan to file more than 30 ANDAs in the next 2 years, of which more than 50% will be complex products.
  • The company filed Ranibizumab in EU during the quarter and is looking forward to the US filing in the coming quarters.
    Show source
    We successfully filed Ranibizumab in EU during the quarter and are looking forward to the US filing in the coming quarters.
  • The company is building a respiratory pipeline using its capabilities and R&D opportunities in green propellants to develop meter dose inhalers that are more climate-friendly and differentiated for patients and the market.
    Show source
    Simultaneously, we are also building a pipeline in the respiratory front with the capabilities we have; on the R&D side, the opportunities that we have on the green propellant front, to take the meter dose inhalers and come up with more climate -friendly and achieving both our sustainability goals and offering a differentiated product to the patients and the market.
  • The company is continuing to innovate on its respiratory pipeline. Replaced by a later filing.
    Show source
    We continue to innovate on that front on the pipeline.
  • Capital expenditure will come along with its strategy. Replaced by a later filing.
    Show source
    Nilesh Gupta: No, it'll come along with the strategy.

Demand and pricing

  • Spiriva TRx share reached 38% in January and NRx was 40% plus; the company hopes to sustain this level through the rest of the quarter and into the next fiscal year to reach overall market share of 40% plus.
    Show source
    Vinita Gupta: So the team has done a really good job in activating multiple are as from a conversion standpoint, but we're starting to see some impact already in January where TRx share has become high 30's has gone to 38% level and NRx is 40% plus.
Show 4 more statements

Demand and pricing

  • Respiratory portfolio had high market shares in key products including Albuterol and Arformoterol.
    Show source
    Our respiratory portfolio continued their strong performance with high market shares in most key products like Albuterol and Arformoterol.
  • Nilesh Gupta said the market’s focus on respiratory has been more on anti-infectives and less on MDI and DPI inhalation products.
    Show source
    I think the focus right now from a respiratory perspective in the market has been more on anti-infectives and the like, not so much MDI, DPI inhalation kind of products.
  • Efforts to ease patient access to Medicare and Medicaid through co-pay assistance, contracting and other avenues are starting to show results.
    Show source
    So you know the multiple eff orts on from a co -pay standpoint to ease the burden on the patient to access into Medicare/Medicaid through contracting, plus other avenues are starting to show results.

Segments

  • The company wants to build specialty as the third major arm for its global business, with the US as a major focus.
    Show source
    Vinita Gupta: So we do want to build specialty as the third major arm for our global business with the US being a major focus.

Risks, rules and outside factors

Outside factors

  • The company has seen tailwinds in input costs. Replaced by a later filing.
    Show source
    We have seen also tailwinds when it comes to input costs.
  • The company has forex tailwinds that are uncertain. Replaced by a later filing.
    Show source
    Ramesh Swaminathan: So there are some tailwinds in terms of forex which you cannot be sure about.

Rules and policy

  • The company received EIRs for Aurangabad and Dabhasa so far this year and completed inspections at Somerset and Nagpur Injectable Facility with zero observations.
    Show source
    So far this year, we have received EIRs for Aurangabad and Dabhasa and have successfully completed inspections at Somerset and Nagpur Injectable Facility with zero observations.
  • The company received the EIR from the USFDA for its Pithampur Unit-1 manufacturing facility with VAI classification during the quarter. Replaced by a later filing.

Everything else said on the call

What management stressed

  • The company is investing in respiratory platforms like Ellipta and Respimat, complex injectable platforms including iron colloids, peptides, 505 b(2)s and long acting Injectables, and a growing portfolio of biologics.
    Show source
    Our R&D capabilities and pipeline are gaining momentum, be it our investments in various respiratory platforms like Ellipta and Respimat or the focus on complex platforms in injectables like iron colloids, peptides, 505 b(2)s and long acting Injectables and also our growing portfolio of biologics.
  • The company is creating green propellant programs for its respiratory franchise.
    Show source
    We are also creating some unique differentiators like green propellant programs for our respiratory franchise.

Group structure

  • The company would be comfortable with a bite-size acquisition of USD 200 million to USD 250 million.
    Show source
    Ramesh Swaminathan: But having said that, we would be comfortable with a bite-size acquisition, USD 200 million to USD 250 million should be easy enough for us.
  • The company acquired the Huminsulin range of products from Eli Lilly and three trademarks from Boehringer Ingelheim for the Indian market.
    Show source
    We are very pleased to strengthen our diabetes portfolio by acquiring the Huminsulin range of products from Eli Lilly Page 2 of 18 February 12, 2025 and also 3 trademarks from Boehringer Ingelheim for the Indian market.
  • The company is looking at late-stage assets that are compelling from an investment perspective, alongside on-market assets.
    Show source
    So we're also looking at late -stage assets that are compelling from an investment perspective.
  • The company has not earmarked funds but is committed to exploring and closing acquisitions for the right assets wherever possible.
    Show source
    We haven't earmarked but are committed for the right assets to explore as well as close wherever possible, both acquisitions.
Show 2 more statements

Group structure

  • Acquisition priorities are India, specialty and then generics, with specialty and India as the major focus.
    Show source
    With specialty and India being the major focus.
  • The company is looking at a combination of pipeline and late-stage assets. Replaced by a later filing.
    Show source
    So a combination of both pipeline as well as late -stage assets is what we're looking at.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Kunal Dhamesha: And can you suggest the probable timelines of that? Tolvaptan is I believe is quarter one FY26 but on glucagon and Risperdal Consta, is there any update in terms of approval?

    Answer, vinita gupta

    Vinita Gupta: So we are making progress on both applications with the agency and would expect that hopefully, approval sooner rather than later. But I think it'll be safe to assume that Tolvaptan would be the major contributor in the first half of the fiscal year and the injectables should ramp up in the second half very nicely.

  2. Question

    Kunal Dhamesha: And the recent inspection at Somerset, has that anything to do with our Risperdal Consta filing? Was it a PAI? Vinita Gupta Yes, it was a PAI but for a suspension product, for Edaravone. The Risperdal Consta product comes from Netherlands, and is manufactured at a CMO and both were inspected by the FDA last year and progressing well. Kunal Dhamesha And second one on the India business. We have cited that the slow growth is primarily due to issues in respiratory therapy, and I believe the respiratory therapy growth itself was quite low despite being in a winter season. So what are the factors that is leading to the slower growth in your view?

    Answer, nilesh gupta

    Nilesh Gupta: I mean the market seems to be that way. I mean sequentially the number is as an absolute number up actually for respiratory, but it's been lagging for a while versus the rest of the market. Even for nine months, the market was only at 4%. We were at 3% for nine months and I mean the quarter again has been disappointing. I do think it'll bounce back. I mean we've had periods of high double-digit growth on respiratory but for the last 12-16 months, it's just been slow. I think the focus right now from a respiratory perspective in the market has been more on anti-infectives and the like, not so much MDI, DPI inhalation kind of products.

    Answer, nilesh gupta

    But we believe that it'll bounce back, hopefully in the next couple of quarters.

  3. Question

    Kunal Dhamesha: Inhalers, right?

    Answer, nilesh gupta

    Nilesh Gupta: Yes, primarily MDI, DPI, a little bit of nebulization. That's it.

    Answer, vinita gupta

    Vinita Gupta: Your voice was very muffled, but if we got your question correctly, you're asking about the reason for the R&D spend ramping up. A good part of it is our complex generics portfolio. It's five nasal sprays actually that we expect to file in Q4 versus the rest of the year. So majority of the spend is coming into quarter four. Also injectables, there's a good amount of increase in the second half of the fiscal year. So it's primarily respiratory and injectables.

    Answer, nilesh gupta

    Nilesh Gupta: In India on the institutional business. I mean it's been fairly flat. It's been a meaningful number. It will continue into the next year as well. But I mean, we always call out the business with and without. The India Region Formulation business, which is the domestic sales business, is 5.8% year-on-year or 9.1% for nine months.

    Answer, nilesh gupta

    Nilesh Gupta: Yes. I mean it's a good number and it will continue with that good number.

    Answer, vinita gupta

    Vinita Gupta: So no change in terms of litigation status. We continue to navigate through that process. In the meantime, the generic substitution has gone up. The overall available market has gone up and our share has ramped up nicely as well. So no real change from a competitive scenario standpoint from the litigation developments.

    Answer, vinita gupta

    Vinita Gupta: As we navigate through all of the outcomes of litigation, I mean, we expect in the first quarter of next fiscal year to get a decision on Mirabegron 2 patent and continue to litigate the others. So definitely for this fiscal year, we don't Page 8 of 18 February 12, 2025 expect any change and then we'll determine the next fiscal year based on the outcome of litigation.

    Answer, bino pathiparampil

    Bino Pathiparampil: One last question to Ramesh. We have been benefiting from this PLI-related income. How long is it likely to continue? How many more quarters?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: The benefit is there for next three years.

    Answer, bino pathiparampil

    Bino Pathiparampil: But I believe you are booking up front or so. So at the current level, how long will it continue? How many quarters?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: So there would be a decline for sure next year. In the normal course, you would be expected to look at about INR 200 crores on an annual basis. But you have the benefit of actually taking up to a third more in a particular year alone, which we've taken advantage of this year. But obviously, it would impact on the total quantum of monies that you can claim over the next three years.

    Answer, ramesh swaminathan

    Ramesh Swaminathan: So it's basically coming in from litigations, and we don't talk about which litigation and the like. It's a conservative provision and that's what it is.

  4. Question

    Surya Patra: There is nothing to anticipate or nothing to see any kind of risk relating to the Mirabegron right now?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: No. Surya Patra: Second question is on the respiratory portfolio as a whole.

  5. Question

    If I remember right, then respiratory has become a more than 30% of revenue contributor putting all geography put together. And the current period is a kind of a respiratory pro respiratory season. So what kind of performance that you would have seen for the overall respiratory portfolio for the quarter?. We have seen moderation, let's say, in India, we have seen some kind of competition in the US relating to Albuterol to be specific. So given that, is there any risk that one should think or consider about this portfolio?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: You know, the secular trends would kind of indicate that respiratory is going to be very important for us in America and in other parts of the globe and of course India as well. There would be some quarter-on-quarter variations and the like. And that doesn't necessarily mean that the secular trend is going to be upended.

  6. Question

    Surya Patra: But this is a kind of a peak seasonal period. During that period, we are witnessing relatively underperformance. That’s why the question was.

    Answer, ramesh swaminathan

    Ramesh Swaminathan: You can't pinpoint the reason why there is a decline in any part in India and so on. So we just take it as it comes that way. But in a general sense, our focus on the segment will certainly continue. Page 9 of 18 February 12, 2025 Vinita Gupta: So it's a really strong contribution both in US, Europe, Canada, as well as growing in other parts of the world like Australia.

    Answer, vinita gupta

    And of course in India, we have the respiratory market growth at a muted level that is contributing to the lower growth. But ove rall, respiratory still continues to be a major therapy area for the organization. It's an area where we expect to bring all the material generic products to market across the globe and we expect to also innovate like we have done in India w ith the two triple novel combinations. We continue to work on respiratory green propellants for US, Europe as well as India plus other products we have the opportunity to bring to market , brands like Xopenex® in the US that have been fairly s table. And while we have a low growth in respiratory in India, we're seeing the flu season pick up in the US again, we're seeing another peak. So the market shares on the respiratory portfolio is fairly strong.

  7. Question

    Surya Patra: Last question is about the cost. It is great to see your cost optimization measures really contributing to the improved margin now , and also possibly improved margin is flowing from the improvement what we have been seeing in the US business as a whole. So there would be an element of Mirabegron which could be a positive surprise. So given that, going ahead, in the next 12 - month period, what kind of a margin performance that we should see for the US business? I may not require the number, but qualitatively if you can talk something about the next year's US profitability that we are anticipating?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: So there are some tailwinds in terms of forex which you cannot be sure about. But the focus on cost is eternal insofar as we are concerned and we have seen some good results coming in. We have seen also tailwinds when it comes to input costs. But again, as I said, there are geopolitical tensions, et cetera that are actually moving parts. You can’t be certain. But I think if you talk about overall margins, I did indicate the fact that between 22.5% to 23.5% would be a good range to aim for the next fiscal as well.

  8. Question

    Surya Patra: Also, are you really worried about the kind of tariff things which has been talked about? Although it has been indicated to be around 2.5% on the pharma also or any US tariff thing area of concern or uncertainty for this moment?

    Answer, vinita gupta

    Vinita Gupta: So we are monitoring it very carefully and the industry has made a strong pitch, both from AAM standpoint as well as IPA, the tariffs will have a significant impact on the generic industry if it was implemented. I mean 70% of generic drugs for the US are imported at present, 50% of generics come from India. So there's clearly a significant role that India plays on the generic front and we've made that case with all the major stakeholders. So we'll find out with the current visit of the PM to the administration what transpires. But we are hoping that pharmaceuticals and generic drugs in particular will be exempted. And if it’s otherwise, we'll be looking at other ways and means of mitigating the impact with a combination of manufacturing in the US as well as wherever possible, from a cost perspective and otherwise. We are watching it very carefully, but hopeful that the case made by the industry has been heard and the implication is understood that any tariff impact can really cause more product disruption and drug shortages which no one wants in the country.

  9. Question

    Anubhav Agarwal: The Somerset where you have the P AI on Radicava?

    Answer, vinita gupta

    Vinita Gupta: I think it's out for a good number of years. It's not in the next two years.

  10. Question

    Anubhav Agarwal: Second is on the Canada - Semaglutide opportunity. Would you be in the first year of the opportunity or are you pursuing that?

    Answer, vinita gupta

    Vinita Gupta: So we do want to build specialty as the third major arm for our global business with the US being a major focus. And assets like Xopenex® is a sweet spot for us, products that fit strategic aspirations, building on the respiratory front and ideally on market assets. But we know it's difficult to really get on market assets. So we're also looking at late -stage assets that are compelling from an investment perspective. And you know that we are a debt-free company at this point, so have the ability to invest for the right programs and opportunities. We haven't earmarked but are committed for the right assets to explore as well as close wherever possible, both acquisitions. Simultaneously, we are also building a pipeline in the respiratory front with the capabilities we have; on the R&D side, the opportunities that we have on the green propellant front, to take the meter dose inhalers and come up with more climate -friendly and achieving both our sustainability goals and offering a differentiated product to the patients and the market.

    Answer, vinita gupta

    We continue to innovate on that front on the pipeline. So a combination of both pipeline as well as late -stage assets is what we're looking at. Bansi Desai : And given the biotech funding has been weak out there in the US, i s it fair to assume that there are good assets that are available in the market?

    Answer, vinita gupta

    Vinita Gupta: There's a lot of opportunities right now that if one could acquire at least a few assets that are meaningful. So really good opportunity to acquire assets. Bansi Desai : Secondly on the Tolvaptan opportunity. Post exclusivity, how should we see the competition coming in? Would it be in a staggered manner and would Tolvaptan be a meaningful contributor in fiscal '27 as well for us? Page 11 of 18 February 12, 2025 Vinita Gupta: We expect it to have a stronger tail because it's a specialty product, REMS product.

    Answer, vinita gupta

    It's the conversion we expect is going to be slower than what you would expect in a simple oral solid and the tail should be longer. So we would expect both second half of the fiscal year as other competition comes in, plus into fiscal year '27, it should be a meaningful product.

Show 11 more questions
  1. Question

    Bansi Desai: And lastly, in terms of margin trajectory, two years out, when I just look at some of the moving parts, probably PLI would have been normalized. Jynarque® also would have been probably at normalized levels. But then again, you have certain businesses in India which are probably loss -making today and that could probably contribute positively. So how should we think about margins, say, in fiscal '27-28? Would fair to assume it would be higher than where we are currently?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: Given the kind of products that we'll be bringing to the market, obviously the top-line buoyancy would continue. There's also the focus on cost and we have taken up a number of initiatives which would actually certainly keep that on a tight leash. And the third aspect of the entire program that you spoke about is essentially adjacencies. Clearly, we are losing about a couple of percentage points because of essentially the losses that these adjacencies are currently lapping up at this stage. But that said, over the next three years, we expect that to also turn positive. But we also have growth plans in terms of spinning it off at some point. So clearly, upward movement on the EBITDA front is certainly to be expected.

  2. Question

    Saion Mukherjee: So Vinita, Nilesh, if you can talk about Semaglutide, other than Canada, which all markets you already filed. And if you can take us through 2026 and 2027, how should we think about the launches? And your preparedness in terms of formulation and API? And how much will be the dependence on partners for this product? So if you can just draw the landscape broadly for this product over the next two years?

    Answer, nilesh gupta

    Nilesh Gupta: I think on India - on the injectable, I mean there's going to be many players. We'll have it in that first wave as well. The more interesting part to solve for in India is the oral product, and we're hoping to have that at the time of loss of exclusivity as well. We think that that will be the more important product to deliver on and that will come from an internal development. And then for other markets, we're obviously looking across, I mean Canada we talked about earlier. But Vinita, do you want to add for other?

    Answer, vinita gupta

    Vinita Gupta: For the oral solid, which is an opportunity also in multiple markets, we have internal development. And for the injectable Semaglutide, we have partnerships in place. For a few markets, we have existing partnerships, others in the works. But we would expect the '27 calendar year to be in at least a handful of the open markets for Semaglutide. Saion Mukherjee: And in terms of capacity, anything you can share? Your ability to service the markets? Have you invested in that from a formulation perspective?

    Answer, vinita gupta

    But right now, we are counting on partners for the injectable.

  3. Question

    Saion Mukherjee: And next one was on green propellant. You mentioned Vinita about that opportunity. So how should we think about it? When do we get more clarity on this? And how meaningful this opportunity you see at this point?

    Answer, vinita gupta

    Vinita Gupta: So we expect the metered dose inhaler market will move materially, maybe starting in five years, but definitely over the 10 years into the green propellant products certainly with the moves that the major pharma companies have made like GSK, AstraZeneca, as well as Chiesi. From a European standpoint, we hope to be at the forefront as a material player on the respiratory front , with our Xopenex® brand as well as other MDIs to bring better propellant products to the market. So we have multiple products in development right now, not at the stage where we are filing in the next year but cer tainly year next, fiscal year '27, we should start to see product filings.

  4. Question

    Saion Mukherjee: One more question regarding biosimilars. We sense that the investments slowed down in the recent past. Any fresh thoughts there? Are you planning to step up investments in biosimilars? Any view you have on that space and Lupin’s participation?

    Answer, vinita gupta

    Vinita Gupta: Actually, it's a promising trend on the biosimilars front in the US in particular in the last 12 months, both from a regulatory perspective with the FDA easing the requirements on interchangeability, you don't need to do additional studies for interchangeability anymore. And with the trend on private labels from the large PBMs like with Caremark and Humira, what they did with the Sandoz, the Cordavis label that converted the majority of the market from Humira to the biosimilar, that is a prom ising trend on the market front. In the past, as we looked at it, both from a development perspective, we saw the biosimilars were fairly onerous, capital intensive, and then from a go -to- market standpoint you needed commercial infrastructure and both seem to start easing up at this point . So it's a really positive trend. I mean we have a good number of products for the near term, so we continue to invest in those. As I mentioned, Ranibizumab was filed in EU this past quarter, will be filed in the US. So we have Pegfilgrastim that we still see as an opportunity, as we get the product approved.

    Answer, vinita gupta

    We have Ranibizumab, Aflibercept, and then Etanercept in '29 that comes into the market in the US where we should be one of three in the market and th en we have other products like Ce rtolizumab and Mepolizumab respiratory products as well that we are pursuing. So actually, it looks like the biosimilar market is starting to open up and , as it does, we'll continue to look at opportunities . As it opens up and on the one side the challenges come down, but the competition goes up. So our focus is very much going to be in limited competition products where we're going to be in the first wave, where we can be one of two, one of three. That is the kind of focus that we will have from a portfolio standpoint. So it will be a fairly selective number of products that we will pursue. Page 13 of 18 February 12, 2025 Moderator: The next question is from Shyam Srinivasan.

    Answer, vinita gupta

    Vinita Gupta: So you know, respiratory portfolio has been a big contributor in the European growth, in particular in the UK as well as Germany, where we've continued to grow our market share with Luforbec®. And now with the Nalcrom® addition in Germany in particular that's helped us grow Germany, you know, the combination of Luforbec® as well as Nalcrom®. So respiratory portfolio has been a big contributor for the European growth and we expect, you know, to continue revenues at the current level. So, wherev er we can, we will grow share. We are getting into new markets in Europe as well. Right now we are in 13 countries with Luforbec® but have the potential of launching in countries like Spain and others. So continue to make inroads there.

  5. Question

    Neha Manpuria: And would you like to earmark a number as to what we would like to spend in, India or US generic in case of acquisitions?

    Answer, vinita gupta

    Vinita Gupta: I think Ramesh meant to say, you know, India , Specialty and then gene rics, wherever we need it, in that order. With specialty and India being the major focus.

  6. Question

    Neha Manpuria: We don't have like an earmark number as to this is what we would like to invest in, let's say, India, Specialty?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: But having said that, we would be comfortable with a bite-size acquisition, USD 200 million to USD 250 million should be easy enough for us.

  7. Question

    Neha Manpuria: And have you earmarked the Cap ex for this, Nilesh?

    Answer, nilesh gupta

    Nilesh Gupta: No, it'll come along with the strategy.

  8. Question

    Harsh Bhatia: Spiriva market share for FY25, our t arget was somewhere around 35% - 40%. In December, as for the presentation, it's around 30% - 31%. So what are the plans for Spiriva market share at this stage, including commercial versus Medicare and Medicaid channel?

    Answer, vinita gupta

    Vinita Gupta: So the team has done a really good job in activating multiple are as from a conversion standpoint, but we're starting to see some impact already in January where TRx share has become high 30's has gone to 38% level and NRx is 40% plus. So you know the multiple eff orts on from a co -pay standpoint to ease the burden on the patient to access into Medicare/Medicaid through contracting, plus other avenues are starting to show results. So we are hopeful that we sustain this level into the rest of the quarter and into the next fiscal year to get the overall market share to hopefully 40% plus.

  9. Question

    Harsh Bhatia: And this is sort of related to the out -of-pocket capping that the innovator had undertaken let's say a few months back. Does that sort of relate to that in any extent?

    Answer, vinita gupta

    Vinita Gupta: We assume that additional competition comes in, in the second half of the year. On Mirabegron, we've assumed that Albuterol faces competition or impact of competition that has already started. And we've assumed that Tolvaptan helps tremendously in the first half and injectables plus Tolvaptan in the second half.

  10. Question

    Tushar Manudhane: Just continuing on R&D spend. While we have highlighted INR 1,750 crores to INR 1,800 crores for FY25.,would you follow it for FY26 as well? On an absolute basis, how much R&D spend will be?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: I would say, as an absolute there would be an increase but as a percentage of sales, it will perhaps be around the same levels. But given the focus that we have on more complex stuff and the like, this is inevitable.

  11. Question

    Tushar Manudhane: And just if you could share specifically for Canada Semaglutide, like market in terms of units, how big it could be?

    Answer, vinita gupta

    Vinita Gupta: Thank you. Hopefully, we have been able to answer all your questions. We'll be happy to take any that we have not been able to get to offline. There were a lot of questions on what is likely to happen in the US from a tariffs perspective. And as I mentioned, we hope that the industry efforts do pay off in terms of to ensure the sustainability of the US generic industry in the interest of patients as well as other stakeholders. From a Lupin standpoint, we are very pleased with how the company has performed this fiscal year and really excited with the potential in the near Page 17 of 18 February 12, 2025 term with our major growth drivers, looking very clear from an approvability standpoint as well as market launch standpoint, and improving market conditions in new areas for Lupin like biosimilars. We look forward to continue to execute on our strategic plan to drive growth across key major markets and evolve our business from generics into more branded and specialty on top of complex generics in the year ahead and certainly in the next couple of years.

Questions about this call

When was the Lupin Q3 FY25 earnings call transcript filed?
Lupin filed the transcript with the exchange on 19 Feb 2025. This page is built from that transcript.
What does this page list?
69 statements from the transcript across 10 topics, 35 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 21 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Lupin Q3 FY25 concall: Lupin expects margins in the range of 22%-23% in the current fiscal year · DalalOS